Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.

Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81%) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88%). In HCC, 17% of samples displayed a high COX-2 expression, and 37% of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription-PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.

[1]  M. Monden,et al.  Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Masferrer,et al.  Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. , 1999, Gastroenterology.

[3]  J. Tang,et al.  Liver resection for hepatocellular carcinoma in octogenarians. , 1999, Surgery.

[4]  T. Fahey,et al.  Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. , 1999, Cancer research.

[5]  T. Kawaguchi,et al.  Expression of cyclooxygenase‐2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation , 1999, Hepatology.

[6]  I. Schieren,et al.  Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells , 1999, Oncogene.

[7]  A. Castonguay,et al.  Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. , 1998, Cancer research.

[8]  J. Morrow,et al.  Meloxicam inhibits the growth of colorectal cancer cells. , 1998, Carcinogenesis.

[9]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human lung carcinoma. , 1998, Cancer research.

[10]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[11]  M. Hori,et al.  Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. , 1998, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  M. Taketo,et al.  Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. , 1998, Cancer research.

[13]  T. Sugimura,et al.  Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. , 1998, Carcinogenesis.

[14]  A. Levine,et al.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. , 1998, Cancer research.

[15]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[16]  I. Singer,et al.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. , 1998, Gastroenterology.

[17]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[18]  S. Meltzer,et al.  Advances in Brief Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett ' s Esophagus and Associated Adenocarcinomas 1 , 2006 .

[19]  T. Nabika,et al.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver , 1998, Hepatology.

[20]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[21]  D. Scollard,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. , 1998, Journal of the National Cancer Institute.

[22]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[23]  T. Sugimura,et al.  Suppression of Intestinal Polyp Development by Nimesulide, a Selective Cyclooxygenase‐2 Inhibitor, in Min Mice , 1997, Japanese journal of cancer research : Gann.

[24]  J. Vane.  Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice. , 1997, Japanese journal of cancer research : Gann.

[25]  E. Okajima,et al.  Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. , 1997, Carcinogenesis.

[26]  L. Schwartz,et al.  Automated Double Labeling of Proliferation and Apoptosis in Glutathione S-transferase-positive Hepatocytes in Rats , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  N. Yoshimi,et al.  Apoptosis Induced by NS‐398, a Selective Cyclooxygenase‐2 Inhibitor, in Human Colorectal Cancer Cell Lines , 1997, Japanese journal of cancer research : Gann.

[28]  J. Morrow,et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.

[29]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. , 1997, Cancer research.

[30]  A. Kakita,et al.  Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus‐associated cirrhosis and HCC , 1997, Cancer.

[31]  M. Runge,et al.  Hypoxia Induces Cyclooxygenase-2 via the NF-κB p65 Transcription Factor in Human Vascular Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[32]  W. Jiménez,et al.  Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. , 1996, Hepatology.

[33]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[34]  T. Kin,et al.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. , 1996, Annals of surgery.

[35]  K. Seibert,et al.  Advances in Brief Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis ' , 2006 .

[36]  D. Huhn,et al.  Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). , 1996, Nucleic acids research.

[37]  T. Kin,et al.  Influence of Associated Viral Hepatitis Status on Recurrence of Hepatocellular Carcinoma after Hepatectomy , 1996, World Journal of Surgery.

[38]  E. Sigal,et al.  Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. , 1996, British journal of rheumatology.

[39]  J. Maclouf,et al.  Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. , 1996, Experimental cell research.

[40]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[41]  N. Okamoto,et al.  Role of Increased DNA Synthesis Activity of Hepatocytes in Multicentric Hepatocarcinogenesis in Residual Liver of Hepatectomized Cirrhotic Patients with Hepatocellular Carcinoma , 1994, Japanese journal of cancer research : Gann.

[42]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[43]  R. Everson,et al.  Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study , 1994, Epidemiology.

[44]  J. Morrow,et al.  Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. , 1994, The Journal of clinical investigation.

[45]  A. Ford-hutchinson,et al.  Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.

[46]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[47]  R. Hardman,et al.  Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. , 1993, Archives of biochemistry and biophysics.

[48]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[49]  P. Ternes,et al.  An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. , 1993, BioTechniques.

[50]  K. Tanikawa,et al.  The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound‐guided fine‐needle biopsy with those of autopsy , 1992, Cancer.

[51]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Okuda,et al.  Hepatocellular carcinoma: Recent progress , 1992, Hepatology.

[53]  P. Vielh,et al.  Sulindac causes regression of rectal polyps in familial adenomatous polyposis. , 1991, Gastroenterology.

[54]  M. Makuuchi,et al.  Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma , 1990, The Lancet.

[55]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[56]  K. Schrör,et al.  Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.

[57]  H. Kawasaki,et al.  Cyclooxygenase-2 expression in hepatocellular carcinoma. , 1999, Hepato-gastroenterology.

[58]  澤岡 均.  Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice , 1999 .

[59]  G. Cattoretti,et al.  Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.

[60]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (part I). , 1998, Journal of the National Cancer Institute.

[61]  B. Gellersen,et al.  Cloning of guinea pig cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase complementary deoxyribonucleic acids: steroid-modulated gene expression correlates to prostaglandin F2 alpha secretion in cultured endometrial cells. , 1997, Endocrinology.

[62]  J. Travers,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1992, The New England journal of medicine.

[63]  P. Romeo,et al.  Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.